Every year new drugs hit the market. Some become superstars while others are left out of sight for good. The pharmaceutical industry is mostly getting a kick out of drugs made for the treatment of rare diseases. Let’s take a look at the medicines that are said to become huge hits and earn billions in revenue in 2016.
1. Emtricitabine and Tenofovir Alafenamide (F/TAF)
Emtricitabine and tenofovir alafenamide (F/TAF) by Gilead Sciences and Japan Tobacco is said to earn $2 billion by the end of 2020. This drug is a treatment option for HIV-1 infection. However, what makes this drug different from already available HIV treatment options is that it will be a single dosage drug. Furthermore, the inclusion of TAF makes this drug much more reliable and safer as a treatment for HIV disease. Gilead, the company behind this drug itself believes that this drug will be better than its previously launched HIV treatment medicines.
2. Atezolizumab
Atezolizumab by Roche is another drug that is said to debut in 2016. This drug is marketed as an anti-PD-L1 cancer drug that possesses the powers to inhibit the spread of cancer cells. This drug works on the immune system to launch an attack on cancer, which is why it is said to earn $2.5 billion in revenue by the end of 2020.
3. Obeticholic Acid
Obeticholic Acid by Intercept Pharmaceuticals is a drug for the treatment of liver inflammation caused by fat deposits, also known as non-alcoholic steatohepatitis. Because this live condition doesn’t have a solid approved treatment option available in the market, this drug is said to gain a lot of attention from around the world. Furthermore, the increase in obesity across the world will result in a spread of this disease, which will require more people to opt for an approved treatment option like this drug. The sales revenue of this drug is predicted to be $2.62 billion at the end of 2020.
4. Dupilumab
Dupilumab, made by Regeneron and Sanofi, is said to launch in 2016. This drug is an IL-4/IL=13 contender and is believed to earn massive in sales revenue across the world. This medicine is a treatment option for asthma and eczema with a forecast sales of $2.5 billion. The reason that most industry experts believe that this is going to be a huge hit is that more 25 million people in the US suffer from asthma and another 35 million people suffer from eczema. The huge demand for a more effective treatment for both these conditions will result in the success of Dupilumab.
5. Ocrelizumab
Ocrelizumab by Roche is another drug that might launch in 2016 and gain a lot of attention. In fact, industry experts believe that this drug will earn a staggering $2.7 billion by the end of 2020. This drug is made for the treatment of multiple sclerosis and relapsing. Furthermore, due to the increase side-effects and safety issues in other sclerosis drugs, Ocrelizumab is said to become more popular after its launch. The twice-yearly IV therapy data for the drug also look great.
